Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Bausch + Lomb Buys Novartis Drugs for $1.75 Billion Expanding Eye Care Portfolio
03:45pm, Friday, 30'th Jun 2023
Eye care company Bausch + Lomb said it would pay $1.75 billion to acquire a portfolio of eye care products from Swiss healthcare giant Novartis.
Bausch + Lomb to acquire dry eye treatment from Novartis in potential $2.5B deal
10:13am, Friday, 30'th Jun 2023
Bausch + Lomb Corp has announced plans to buy dry eye disease treatment Xiidra from Swiss pharma giant Novartis AG (ADR) (NYSE:NVS) in a deal that could be valued as high as $2.5 billion. The two comp
Bausch + Lomb to buy ‘dry eye' treatment from Novartis in a $2.5 billion deal
09:33am, Friday, 30'th Jun 2023
Bausch + Lomb Corp. BLCO, +7.98% confirmed that it was buying the “dry eye” treatment Xiidra from Novartis AG NVS, +0.90% NOVN, +0.72% in a deal valued at $2.5 billion. Under terms of the deal, Ba
Bausch + Lomb to buy ‘dry eye' treatment from Novartis in a $2.5 billion deal
09:32am, Friday, 30'th Jun 2023
Bausch + Lomb Corp. BLCO, +7.98% confirmed that it was buying the “dry eye” treatment Xiidra from Novartis AG NVS, +0.90% NOVN, +0.72% in a deal valued at $2.5 billion. Under terms of the deal, Ba
NVS or LLY: Which Is the Better Value Stock Right Now?
12:48pm, Tuesday, 27'th Jun 2023
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Novartis (NVS) or Eli Lilly (LLY). But which of these two stocks is more attractive to value investor
5 Dividend Growth Stocks to Buy for Gains in the Second Half
08:09am, Friday, 23'rd Jun 2023
Toll Brothers (TOL), Walmart (WMT), Caterpillar (CAT), W.W. Grainger (GWW) and Novartis (NVS) could be compelling picks heading into the second half of the year.
There's a 'strong desire' in big pharma to continue to acquire, says JPMorgan analyst
07:15am, Friday, 23'rd Jun 2023
Juha Anjala, co-head of EMEA health-care investment banking at JPMorgan, discusses government support for investment in life sciences, as well as innovation in the sector.
Why Novartis (NVS) is a Top Value Stock for the Long-Term
11:01am, Tuesday, 20'th Jun 2023
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:16am, Tuesday, 20'th Jun 2023
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
10:15am, Monday, 19'th Jun 2023
Cosentyx is highly effective for a skin condition known as hidradenitis suppurativa. The new indication could have blockbuster potential for Novartis.
Novartis Stock Screams Value After Chinook Therapeutics Buyout
08:05am, Tuesday, 13'th Jun 2023
That value proposition took a huge step forward on Monday when Novartis announced a $3.2 billion acquisition of Seattle-based biotechnology company Chinook Therapeutics. A specialist in the developmen
KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against Chinook
04:40pm, Monday, 12'th Jun 2023
Chinook Therapeutics (NASDAQ: KDNY ) has been surging all day. Why? KDNY stock surged on news that multinational pharmaceutical giant Novartis (NYSE: NVS ) will acquire the firm, which is known for ki
Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say
03:40pm, Monday, 12'th Jun 2023
In light of a Novartis NVS, -0.94% deal to acquire Chinook Therapeutics Inc. KDNY, +58.09%, which is developing treatments for a rare kidney disease, two other companies focused on the same disease lo
Novartis (NVS) to Buy Chinook for $3.5B to Strengthen Pipeline
01:43pm, Monday, 12'th Jun 2023
Novartis (NVS) is looking to strengthen its renal pipeline with the acquisition of Chinook Therapeutics for $3.5 billion, which adds two late-stage medicines in development for rare, severe chronic ki
Chinook Therapeutics Shares Soar on Novartis Purchase
12:10pm, Monday, 12'th Jun 2023
Novartis agreed to buy Chinook Therapeutics for up to $3.5 billion.
